The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Immune cells are most commonly engineered to kill cancers, but now, scientists have shown the technique makes the gut lining ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the ...

Researchers have unlocked a way to grow the immune system’s “conductors” from stem cells, bringing ready-made cancer-fighting therapies a big step closer. For the first time, scientists at the Univers ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.